Compare Bristol-Myers Squibb Co (BMY) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.42 (market cap $116.30B), while iShares 7-10 Year Treasury Bond ETF trades at $93.71. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | IEF | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $97.99 |
52-Week Low | $42.60 | $93.11 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
IEF trades at $93.29, down 0.36% on the day, with a bearish technical signal driven by moving averages. The ETF shows neutral oscillators but oversold short-term RSI. Recent news highlights bond ETF inflows and investor focus on yield amid Federal Reserve uncertainty, with articles from Benzinga (July 14, 2026) and CNBC (June 25, 2026) noting record flows and rate hike speculation.
Outlook remains cautious due to interest rate sensitivity and macroeconomic pressures. Risks include potential Fed hikes and inflation concerns, but the oversold RSI may offer short-term support. Investors should weigh yield attractiveness against duration risk in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
